Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)
Trial details
- Registry ID
- NCT04697810
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as CF102
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)NCT04697810 | Can-Fite BioPharma | Phase 2 | Unknown | 2025-04-15Estimated |
| Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 CirrhosisNCT05201404 | Can-Fite BioPharma | Phase 3 | Recruiting | 2026-02Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |